Quantcast

Janssen gets FDA’s green light for Xarelto for prevention of blood clots

The U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding, Janssen said Monday in a press release.

Read more

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.

Read more

Bayer’s Xarelto in deep vein thrombosis treatment confirm low rates of major bleeding seen in pivotal trial

The non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study in patients with cancer-associated thrombosis (CAT) – both showing low rates of major bleeding and recurrent venous thromboembolism (VTE) with Xarelto (rivaroxaban). Results from the two studies were presented at the 2015 ASH Annual Meeting, and XALIA findings were also simultaneously published in the Lancet Haematology.

Read more